Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients

PURPOSE: S-1 is an oral fluoropyrimidine anticancer drug consisting of the 5-fluorouracil prodrug tegafur combined with gimeracil and oteracil. The purpose of this study was to evaluate the pharmacokinetic (PK), bioequivalence, and safety of a newly developed generic formulation of S-1 compared with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hae Won, Seong, Sook Jin, Kang, Woo Youl, Ohk, Boram, Gwon, Mi-Ri, Kim, Bo Kyung, Cho, Seungil, Cho, Kyunghee, Sung, Yong Kyung, Yoon, Young-Ran, Kim, Jong Gwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732657/
https://www.ncbi.nlm.nih.gov/pubmed/31564829
http://dx.doi.org/10.2147/DDDT.S219822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732657/
https://www.ncbi.nlm.nih.gov/pubmed/31564829
http://dx.doi.org/10.2147/DDDT.S219822

Ejemplares similares